Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 1c

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

November 14, 2022 4:01 PM EST

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimers disease continues to progress

Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023

ACU193 was granted Fast Track designation from the U.S. FDA for the treatment of early Alzheimers disease

Cash, cash equivalents and marketable securities of $200.2 million as of Sept. 30, 2022 expected to be sufficient to support clinical and operational goals through 2025

Company to host conference call and webcast today at... More